We are live on
!
Find out more
DCM
DAFNA Capital Management Portfolio holdings
AUM
$440M
1-Year Est. Return
109.12%
This Fund
S&P 500
This Quarter
Est. Return
-10.55%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$353M
AUM Growth
-$40.7M
(-10%)
Cap. Flow
+$13.6M
Cap. Flow
% of AUM
3.86%
Top 10 Holdings %
Top 10 Hldgs %
52.84%
Holding
90
New
8
Increased
24
Reduced
15
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arcus Biosciences
RCUS
|
+$4.3M |
| 2 |
Stoke Therapeutics
STOK
|
+$2.54M |
| 3 |
Denali Therapeutics
DNLI
|
+$2.45M |
| 4 |
Inogen
INGN
|
+$2.35M |
| 5 |
Oric Pharmaceuticals
ORIC
|
+$2.12M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ascendis Pharma A/S
ASND
|
+$3.28M |
| 2 |
Axogen
AXGN
|
+$3M |
| 3 |
AtriCure
ATRC
|
+$1.83M |
| 4 |
BioCryst Pharmaceuticals
BCRX
|
+$877K |
| 5 |
Alkermes
ALKS
|
+$864K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Sutro Biopharma
STRO
$421M
| $284K | 0.08% |
43,708
| – | – |
|
77
Aprea Therapeutics
APRE
$7.83M
| $280K | 0.08% |
137,174
| – | – |
|
78
BiomX
PHGE
$1.85M
| $223K | 0.06% |
21,112
| – | – |
|
|
NVRO
79
DELISTED
NEVRO CORP.
NVRO
| $222K | 0.06% |
38,000
| – | – |
|
80
Black Diamond Therapeutics
BDTX
$112M
| $217K | 0.06% |
140,000
| – | – |
|
81
Spero Therapeutics
SPRO
$73M
| $90K | 0.03% |
125,000
| – | – |
|
82
Tenaya Therapeutics
TNYA
$163M
| $27K | 0.01% |
+47,319
| New | +$46.7K |
|
83
Acrivon Therapeutics
ACRV
$74M
| – | – |
-112,414
| Closed | -$677K |
|
84
Perspective Therapeutics
CATX
$342M
| – | – |
-130,169
| Closed | -$415K |
|
85
Compass Therapeutics
CMPX
$387M
| – | – |
-158,394
| Closed | -$230K |
|
|
CNTA
86
DELISTED
Centessa Pharmaceuticals
CNTA
| – | – |
-47,453
| Closed | -$795K |
|
|
MASI
87
DELISTED
Masimo
MASI
| – | – |
-3,000
| Closed | -$496K |
|
|
SLRN
88
DELISTED
ACELYRIN
SLRN
| – | – |
-87,989
| Closed | -$276K |
|
89
Vir Biotechnology
VIR
$1.49B
| – | – |
-100,000
| Closed | -$734K |
|
Similar funds
CDMG
SCP
CAAM
HCM
BOA
DBG
SPT
BCM
DAFNA Capital Management's Q1 2025 Portfolio in Review
As of Q1 2025, DAFNA Capital Management held 90 positions worth $353M, down 10% from $393M the previous quarter. Its ten largest holdings account for 53% of the portfolio.
DAFNA Capital Management deployed $13.6M of net new capital in Q1 2025, opening 8 new positions and adding to 24 existing holdings. Its largest new stake was Denali Therapeutics: 127,900 shares worth $1.74M.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 86% a quarter earlier.
On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $3.28M trimmed.
- DAFNA Capital Management's largest Q1 2025 buy was Denali Therapeutics: 127,900 shares worth $1.74M.
- DAFNA Capital Management added most to Arcus Biosciences in Q1 2025, an estimated $4.3M increase.
- DAFNA Capital Management's biggest Q1 2025 reduction was Ascendis Pharma A/S, cutting an estimated $3.28M.
- DAFNA Capital Management fully exited Centessa Pharmaceuticals in Q1 2025, selling an estimated $795K.
- DAFNA Capital Management's ten largest holdings make up 53% of its $353M portfolio in Q1 2025.
- DAFNA Capital Management opened 8 new positions and closed 7 in Q1 2025.
- DAFNA Capital Management's portfolio value fell 10% quarter-over-quarter to $353M.
Based on DAFNA Capital Management's 13F filing for Q1 2025, filed 15 May 2025.